Cyteir Therapeutics, Inc.
CYT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -58.6% |
| R&D Expenses | $35 | $31 | $17 | $13 |
| G&A Expenses | $14 | $11 | $4 | $3 |
| SG&A Expenses | $14 | $11 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $0 | -$0 |
| Operating Expenses | $48 | $42 | $21 | $16 |
| Operating Income | -$48 | -$42 | -$21 | -$16 |
| % Margin | – | – | – | -201,312.5% |
| Other Income/Exp. Net | $2 | $0 | $0 | $1 |
| Pre-Tax Income | -$46 | -$42 | -$21 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$44 | -$42 | -$21 | -$15 |
| % Margin | – | – | – | -188,050% |
| EPS | -1.25 | -1.18 | -0.87 | -0.77 |
| % Growth | -5.9% | -35.6% | -13% | – |
| EPS Diluted | -1.25 | -1.18 | -0.87 | -0.77 |
| Weighted Avg Shares Out | 35 | 35 | 24 | 19 |
| Weighted Avg Shares Out Dil | 35 | 35 | 24 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$46 | -$42 | -$21 | -$16 |
| % Margin | – | – | – | -198,625% |